Lung cancer in the middle and late stages can obtain a five-year survival rate of about 5% to 50% after treatment with immunotherapy and other therapies, but it is more difficult to be cured. Lung cancer is a common malignant tumor of the respiratory system, and the occurrence of the disease is related to smoking, environment, heredity and other factors. When the disease develops into middle and late stages, it is often accompanied by lymph node metastasis and distant metastasis. If there is no chance of surgery, the disease is often treated with immunotherapy. This therapy is to improve the patient’s autoimmune function, and commonly used drugs such as nabulizumab, pembrolizumab, and karelizumab, which target PD-1/PD-L1, can be used to improve the patient’s autoimmune function. Often can also be combined with targeted therapy and radiotherapy and other therapies, after active treatment, can prolong the survival of patients, but it is difficult to achieve a cure. Drugs need to be used under the guidance of a doctor, it is recommended that patients maintain a good state of mind, and actively cooperate with the doctor’s treatment, in order to improve the symptoms and prolong the survival period.